Search Medication
| Level | Qualifying studies |
|---|---|
| A | Systematic review or meta-analysis of human trials |
| B | Human RDBPC trials. ≥ 2 studies and/or 1 study with ≥ 50 subjects |
| C | Human RDBPC trials or RCTs. 1 study < 50 subjects |
| D | Human trials or in-vivo animal trials |
| N/A | Insufficient evidence to suggest that any significant nutrient depletions exist |
Results for Losartan: 8
Evidence Rating ScaleCalcium
Summary: Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of calcium in healthy subjects.
Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of calcium in healthy subjects.
Carnitine
Summary: Although this systematic metabolomics study failed to identify circulating metabolites convincingly predicting favorable antihypertensive response to four different drug classes, it provided accumulating evidence linking fatty acid metabolism to human
Although this systematic metabolomics study failed to identify circulating metabolites convincingly predicting favorable antihypertensive response to four different drug classes, it provided accumulating evidence linking fatty acid metabolism to human
Chloride
Summary: Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of chloride in healthy subjects.
Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of chloride in healthy subjects.
CoQ10
Summary: The impairment of energy production and decreased level of lipid-soluble antioxidants in brain mitochondria as well as structural alterations in the basilar artery may contribute to increased vulnerability of brain tissue in hypertension. Long-term treatment with AT1R blockers may prevent brain dysfunction in hypertension.
The impairment of energy production and decreased level of lipid-soluble antioxidants in brain mitochondria as well as structural alterations in the basilar artery may contribute to increased vulnerability of brain tissue in hypertension. Long-term treatment with AT1R blockers may prevent brain dysfunction in hypertension.
Magnesium
Summary: Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of magnesium in healthy subjects.
Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of magnesium in healthy subjects.
Potassium
Summary: Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of potassium in healthy subjects.
Administration of 100mg of losartan during a low-sodium diet for 6 days increases the urinary flow rate and excretion of potassium in healthy subjects.
Sodium
Summary: In subjects on a low-salt diet, losartan markedly increased urinary sodium excretion. Losartan also increased urine flow rate; urinary potassium excretion; and the excretion of chloride, magnesium, calcium, and phosphate.
In subjects on a low-salt diet, losartan markedly increased urinary sodium excretion. Losartan also increased urine flow rate; urinary potassium excretion; and the excretion of chloride, magnesium, calcium, and phosphate.
The blood samples showed significant decrease of the serum sodium and uric acid levels, along with a significant increase of the serum potassium level. The pharmacological actions of losartan at the ordinarily used clinical dose level were confirmed in humans, however, no significant inhibitory effect of the drug on melatonin secretion could be confirmed. These results are expected to be useful for guiding the proper use of angiotensin II receptor blockers.
Zinc
Summary: The available evidence suggests that use of ACE inhibitors and angiotensin 2 receptor antagonists or thiazide diuretics have the potential to reduce zinc levels in hypertensive patients. Additional research using larger participant numbers and accounting for dietary zinc intakes are required.
The available evidence suggests that use of ACE inhibitors and angiotensin 2 receptor antagonists or thiazide diuretics have the potential to reduce zinc levels in hypertensive patients. Additional research using larger participant numbers and accounting for dietary zinc intakes are required.
We found that: 1) Ang-II infusion progressively increased BP, which was accompanied by hypomagnesuria and signs of secondary hyperaldosteronism; 2) an additive effect between Ang-II and a high Na load may have an effect on strontium (Sr), zinc (Zn) and copper (Cu) balances; 3) Dahl SS rats fed a high Na diet had a slow pressor response, accompanied by altered Mg, Na, potassium (K), and phosphate (P) balances; and 4) losartan prevented BP increases induced by Ang II-NaCl, but did not modify mineral balances. In Dahl SS rats, losartan attenuated high BP and ameliorated magnesemia, Na and K balances. Mg metabolism maybe considered a possible defect in this strain of rat that may contribute to hypertension.
These drugs did not affect zinc concentrations in plasma and saliva. It was concluded that losartan and perindopril similarly alter taste sensitivity during repeated dosing of the drugs.
Treatment with losartan causes an increase in urinary Zn excretion and induces Zn deficiency in patients with hypertension. The addition of hydrochlorothiazide has an additive effect. Magnesium and nitric oxide metabolism are not affected by either treatment.
